Merck KGaA spinout gets first funding to bring dual-acting cancer molecules into the clinic
Two and a half years after launch, Merck KGaA spinout iOnctura is getting its first major round of funding.
The oncology startup raised €15 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
